
|Articles|September 1, 2003
Expensive or Good Deal?
Biologics manufacturers cite complex research and development process,along with FDA scrutiny, as reason for costly - but worthy - drugs
Advertisement
Advertisement
Latest CME
Advertisement
Advertisement
Trending on Dermatology Times
1
FDA Accepts Addition of Bemotrizinol as First New Sunscreen Ingredient in 20 Years
2
Dual-Action Microneedle Patch Shows Promise for Psoriasis in Preclinical Study
3
AI Analysis Reveals Menopausal Hair Loss Linked to Systemic Health and Inflammation
4
Novel Botanical Moisturizer Demonstrates Superior Efficacy Over Metronidazole in Phase 2 Rosacea Trial
5














